Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TSC-102
- Development stage
- Preclinical
- Lead developer
- TCRx Therapeutics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
TSC-102 is a T-cell receptor (TCR) engineered T cell therapy developed by TScan Therapeutics. It is designed to treat hematologic malignancies such as Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Acute Lymphocytic Leukemia (ALL). The therapy works by engineering T cells to target CD45, also known as leukocyte common antigen, when presented on specific HLA types (e.g., HLA-A*03:01). This approach aims to induce immunologic cytotoxicity to eliminate residual disease and prevent relapse following allogeneic hematopoietic cell transplantation. TScan Therapeutics utilizes its proprietary TargetScan and ReceptorScan platforms for the discovery and development of these tumor-reactive TCRs.
02
Targets
CD45/HLA-A*03:01 (CD45 peptide–HLA-A*03:01 complex)
Beyond the preview
Go deeper on TSC-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TSC-102.